Compound sulfamethoxazole tablets

This product is a long-acting sulfonamide drug. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae. Sulfonamide drugs are broad-spectrum antibacterial agents. Its mechanism of action is that it is similar to para-aminobenzoic acid (PABA) in structure and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from synthesizing folic acid required by bacteria as a raw material and reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purines, thymine nucleotides and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

Molecular weight: C11H12N4O3S

This product is white or slightly yellow tablets.

This product is suitable for the following infections caused by sensitive bacteria: 1. Urinary tract infections: (urethritis, gonorrhea, syphilis). 2. Intestinal infections: (gastroenteritis, dysentery, etc.). 3. Upper respiratory tract infections (tonsillitis, mycoplasma, chlamydia infection, pneumonia, bronchitis, lung abscess, etc.). 4. Skin and soft tissue infections (cellulitis, burn infection and trauma).

Oral administration for adults: 1g for the first dose, 0.5g each time thereafter, once a day; for children over 2 months old, 15mg/kg per day, double the first dose.

1. Allergic reactions are common and may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and epidermolysis bullosa atrophic dermatitis may occur. There are also serum sickness-like reactions such as photosensitivity, drug fever, joint and muscle pain, and fever. 2. Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. Patients who lack glucose-6-phosphate dehydrogenase (G-6PD) are more likely to develop this condition after using sulfonamides. It is more common in newborns and children than in adults.

1. Patients who are allergic to sulfonamides are contraindicated. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, patients with this disease are contraindicated to use this product. 3. Pregnant and lactating women are contraindicated to use this product. 4. Infants under 2 months old are contraindicated to use this product. 5. Patients with severe liver and kidney damage are contraindicated to use this product.

Precautions for children: Since sulfonamides can compete with bilirubin for binding sites on plasma proteins, and the acetyltransferase system of newborns is not fully developed, the free blood concentration of sulfonamides increases, which increases the risk of kernicterus. Therefore, the use of this type of drug in newborns and infants under 2 months old is contraindicated; since children are in the growth and development period and their liver and kidney functions are not yet perfect, the dosage should be reduced as appropriate. Precautions for pregnancy and lactation: 1. This product can cross the blood-placental barrier to the fetus, and animal experiments have found that it has teratogenic effects. There is a lack of sufficient data for human studies, so pregnant women should avoid using it. 2. This product can be secreted in breast milk, and the concentration in breast milk can reach 50% to 100% of the maternal blood drug concentration. The drug may affect infants. The use of this product in newborns with G-6PD deficiency may lead to hemolytic anemia. In view of the above reasons, this product should not be used by breastfeeding women. Precautions for the elderly: Elderly patients have an increased chance of serious adverse reactions when using sulfonamides. Severe rash, bone marrow suppression and thrombocytopenia are common serious adverse reactions in the elderly. Therefore, elderly patients should avoid using it, and when there is a real indication, the decision should be made after weighing the pros and cons.

1. The combined use of urine alkalinizing drugs can enhance the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with PABA, because PABA can replace this product for bacterial uptake, and the two are mutually antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxicity. Therefore, when these drugs are used at the same time as this product, or when used after the use of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium.

Keep sealed.

Sulfadimethoxine 0.2g, trimethoprim 40mg

24 months

Shanxi Taiyuan Pharmaceutical Co., Ltd.

• Founded in:

  2004-01-15

• Address:

  No. 22, Huagong Road, Jinyuan District, Taiyuan City, Shanxi Province

• Tax NO.:

  91140100757271910U

• Registered Funds:

  215 million yuan

• Website:

  Log in to view

• Email:

  Log in to view